<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04517903</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2019/53</org_study_id>
    <nct_id>NCT04517903</nct_id>
  </id_info>
  <brief_title>Validation Study on Eye Rubbing Questionnaire in Patients With or Suspected of Having a Keratoconus (KC)</brief_title>
  <acronym>QFK</acronym>
  <official_title>Validation Study on Eye Rubbing Questionnaire in Patients With or Suspected of Having a Keratoconus (KC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      KC is a degenerative disorder of the cornea. Keratoconus etiopathogenesis remains unclear and&#xD;
      may rely on environmental and genetic factors. Usually considered as a rare disease&#xD;
      (&lt;1/2000), but the prevalence is nowadays growing worldwide up to 1/500. In that pathology,&#xD;
      cornea progressively gets thinner, and there is a deformation of the corneal surface which&#xD;
      can induce high order optical aberrations and visual impairment.&#xD;
&#xD;
      Eye rubbing is certainly the main factor in the progression or development of keratoconus&#xD;
      (KC), yet it is only very partially evaluated and quantified in current management.&#xD;
      Environmental and clinical factors will be collected and associated with a eye rubbing&#xD;
      Questionnaire, specifically pointing out eye rubbing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CNRK center is working on an eye rubbing questionnaire since 2017 in order to quantify that&#xD;
      pejorative factor. Patient education can limit in a certain amount the Keratoconus&#xD;
      progression. Thus, our objective will be to evaluate the therapeutic impact on Keratoconus&#xD;
      progression of patient's education against eye rubbing according to an eye rubbing&#xD;
      Questionnaire.&#xD;
&#xD;
      The validation of a dedicated questionnaire is an important act that will allow the&#xD;
      scientific evaluation of this factor with both environmental and behavioral traits. It can&#xD;
      thus be integrated into our care activity for its intrinsic educational and therapeutic&#xD;
      virtues and for its decision-making aid for certain treatments. It will be useful first of&#xD;
      all for the refinement of the correct prescription of corneal collagen crosslinking for&#xD;
      evolving KC or KC with a high risk of progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2021</start_date>
  <completion_date type="Anticipated">March 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>eye rubbing questionnaire at baseline and 15 days later for exploratory phase; at baseline and at 6 month follow-up for confirmatory phase and at home</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>validation of our eye rubbing questionnaire</measure>
    <time_frame>Baseline and 15 days after (Day 15)</time_frame>
    <description>validation of our eye rubbing questionnaire will be made through the evaluation of its Suitability (Appearance validity, Content validity), Reliability (Consistency and homogeneity, Reproducibility), Applicability (Feasibility and acceptability), Validity (Construct validity), Sensitivity (Sensitivity to change, Discriminative validity)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>impact of the questionnaire on the reduction or cessation of eye rubbing</measure>
    <time_frame>Baseline and 6 months after (Month 6)</time_frame>
    <description>The evolution of the answers to the questionnaire and of the disease between the visit to M0 and the visit at 6 months will be defined by:&#xD;
A decrease of at least one level in the intensity, or duration, or frequency of eye rubbing&#xD;
Stopping eye rubbing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring the scability of the KC from clinical data</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>The clinical course being determined as follows:&#xD;
Increase in maximum anterior or posterior keratometry (corneal curvature) of more than 1 diopter (D), or&#xD;
Corneal thinning at the thinnest point of the cornea (CTP) of more than 10 microns</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the scalability of the KC at 6 months</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>Estimate the scalability of the KC at 6 months for each of the rubbing categories (reduction of rubbing or not, cessation of rubbing or not)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">470</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>exploratory phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eye rubbing questionnaire at baseline and 15 days later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Confirmatory phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eye rubbing questionnaire at baseline and at 6 month follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>eye rubbing questionnaire</intervention_name>
    <description>eye rubbing questionnaire</description>
    <arm_group_label>Confirmatory phase</arm_group_label>
    <arm_group_label>exploratory phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Coming for the first time for expert advice on KC&#xD;
&#xD;
          -  Having a suspected or known KC&#xD;
&#xD;
          -  Being over 13 years old (or from 13 years old)&#xD;
&#xD;
          -  Possess computer connection equipment (computer, tablet or smartphone) and access to&#xD;
             the network, for the completion of the questionnaire at home.&#xD;
&#xD;
          -  Being affiliated to or beneficiary of health insurance&#xD;
&#xD;
          -  Have signed the informed consent form from the patient and from legal representatives&#xD;
             for minor patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Being incapacitated or unable to follow study procedures&#xD;
&#xD;
          -  Patient under legal protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Touboul, MD-PhD</last_name>
    <phone>+335 56 79 55 30</phone>
    <email>david.touboul@chu-bordeaux.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Touboul, MD, PhD</last_name>
      <phone>+335 56 79 55 30</phone>
      <email>david.touboul@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Beatrice Cochener, MD, PhD</last_name>
      <phone>+332 98 22 34 40</phone>
      <email>beatrice.cochener@ophtalmologie-chu29.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrad</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frederic chiambaretta, MD, PhD</last_name>
      <phone>+334 73 75 14 67</phone>
      <email>fchiambaretta@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline Burillon, MD, PhD</last_name>
      <phone>+334 78 86 14 00</phone>
      <email>carole.burillon@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent Daien, MD, PhD</last_name>
      <phone>+334 67 33 69 66</phone>
      <email>v.daien@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre National Ophtalmologique des Quinze Vingt</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent Borderie, MD, PhD</last_name>
      <phone>+331 40 02 15 11</phone>
      <email>vborderie@15-20.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Muraine, Md, PhD</last_name>
      <phone>+332 32 88 89 90</phone>
      <email>marc.muraine@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Fourni√©, MD, PhD</last_name>
      <phone>+335 61 77 20 57</phone>
      <email>fournie.p@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 14, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Keratoconus</keyword>
  <keyword>Eye rubbing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

